A Critical Literature Review of Health Economic Evaluations in Pertussis Booster Vaccination

Aurelie Millier; Samuel Aballea; Lieven Annemans; Mondher Toumi; Sibilia Quilici

Disclosures

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(1):71-94. 

In This Article

Five-year View

National health authorities have to consider not only health benefits, but also economic aspects when deciding to recommend and fund new vaccination programs. In this framework, health technology assessment of vaccination programs is performed. The latter give a statement/advice to policy decision makers on whether these new vaccination programs should be included in the current national immunization program and funded. Health economic evaluation is often an essential component of this health technology assessment, being a key decision tool in a context of rising budget constraint. Changes in health policy are hardly predictable, making future requirements for economic evaluations of vaccines difficult to anticipate.

In this review, all included analyses used assumptions for several inputs. However, more data will become available, whether from further models or from real-life assessments (data from countries with new vaccination programs). These estimates should be incorporated into new models, so that comparison of different strategies is more precisely performed. The results of clinical trials evaluating the efficacy of maternal immunization should become available by the end of 2012.[101]

In the absence of pertussis booster vaccination, new disease outbreaks are likely to occur in the future, which may strengthen the economic case for vaccination in coming years.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....